A recent DSUVIA study noted a significant decrease in the amount of opioids used in the post-anesthesia care unit, according to Pamela Palmer, MD, PhD, co-founder and CMO of AcelRx Pharmaceuticals.
Study results also found a substantial decrease in the time to discharge from the post-anesthesia care unit for patients treated with DSUVIA, compared to historical controls.
AcelRx Pharmaceuticals continues to explore the efficacy of DSUVIA in intra- and postoperative care, and aims to engage in further studies examining its use outside of post-surgical care.
*Note: This article was updated to clarify that study results showed a substantial decrease in the time to discharge form the PACU for patients treated with DSUVIA. The original article reported a “substantial increase” in that time and was corrected at 12:25 pm CST on Aug. 27.
More articles on orthopedics:
$2.8M+ NIH grant awarded to Steadman Philippon Research Institute for stem cell research
Ohio health system expands robotic offerings for spine, brain surgery
Dr. Richard Berger: Potential for delays makes now ‘the best time to get surgery’
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
